Latest Graft-versus-host disease Stories
AMSTERDAM, December 9, 2014 /PRNewswire/ -- ~ Data confirms the potential of ATIR(TM) in partially matched hematopoietic stem cell transplants ~ Kiadis Pharma
Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.
A new study found in the latest issue of STEM CELLS Translational Medicine reports that researchers may have found a solution to the rejection of transplanted tissue that is used along with immuno-suppression
AMSTERDAM, October 30, 2014 /PRNewswire/ -- Kiadis Pharma B.V.
AMSTERDAM, September 3, 2014 /PRNewswire/ -- ~ Clinical and Business Development expert re-joins the Company ~ Kiadis Pharma B.V.
MarketOptimizer.org adds “OpportunityAnalyzer Graft-Versus-Host Disease – Opportunity Analysis and Forecasts to 2018” to its store.
ReportsnReports.com adds “EpiCast Report Graft-Versus-Host Disease - Epidemiology Forecast to 2023” to its store.
Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease.
Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease.
Research demonstrates association between diversity of gut bacteria and survival WASHINGTON, June 17, 2014 /PRNewswire-USNewswire/ -- New